Compliant endovascular balloon reduces the lethality of superior vena cava tears during transvenous lead extractions

Ryan Azarrafiy, Darren C. Tsang, Thomas A. Boyle, Bruce L. Wilkoff, Roger Carrillo

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: Superior vena cava (SVC) lacerations have been identified as the most lethal complication encountered during cardiac implantable electronic device lead extraction. The case fatality rate of these events approximates 50% due to rapid exsanguination. A novel, compliant balloon specifically designed for use in the SVC may provide hemostasis in the event of endovascular perforation. By temporarily occluding the compromised vessel, the endovascular balloon should delay hemodynamic collapse, provide a more controlled surgical field for repair, and thereby reduce the mortality of SVC tears complicating transvenous lead extraction. Objective: To assess the early impact of the compliant endovascular balloon on the management of SVC tears and survival outcomes. Methods: We searched a publicly available, United States Food and Drug Administration-maintained database for adverse events from 1 manufacturer of lead extraction tools. Reports from July 1, 2016, to December 31, 2016 were reviewed by 2 physicians to identify instances of SVC tears. Extracting physicians were contacted for further case details. Confirmed SVC tears were analyzed for patient demographics, repair strategies, and index hospitalization mortality. Results: Of the complications reported, 35 cases of surgically confirmed SVC tears were identified. One hundred percent of patients (9/9) were discharged alive when the endovascular balloon was properly utilized, compared to 50% of patients (13/26) when the device was not used (P = .0131). Differences between all other variables analyzed were statistically insignificant. Conclusion: During the study period, we observed a reduction in mortality in patients who suffered SVC tears while undergoing lead extraction when treatment included an endovascular balloon.

Original languageEnglish (US)
JournalHeart Rhythm
DOIs
StateAccepted/In press - 2017

Fingerprint

Superior Vena Cava
Mortality
Exsanguination
Physicians
Equipment and Supplies
Lead
Lacerations
United States Food and Drug Administration
Hemostasis
Hospitalization
Hemodynamics
Demography
Databases
Survival

Keywords

  • Balloon
  • Cardiac device
  • Endovascular
  • Laceration
  • Lead extraction
  • Repair
  • Superior vena cava
  • Tear

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Compliant endovascular balloon reduces the lethality of superior vena cava tears during transvenous lead extractions. / Azarrafiy, Ryan; Tsang, Darren C.; Boyle, Thomas A.; Wilkoff, Bruce L.; Carrillo, Roger.

In: Heart Rhythm, 2017.

Research output: Contribution to journalArticle

Azarrafiy, Ryan ; Tsang, Darren C. ; Boyle, Thomas A. ; Wilkoff, Bruce L. ; Carrillo, Roger. / Compliant endovascular balloon reduces the lethality of superior vena cava tears during transvenous lead extractions. In: Heart Rhythm. 2017.
@article{0f0b3e9f94404b10bd3fd0bf6754a60b,
title = "Compliant endovascular balloon reduces the lethality of superior vena cava tears during transvenous lead extractions",
abstract = "Background: Superior vena cava (SVC) lacerations have been identified as the most lethal complication encountered during cardiac implantable electronic device lead extraction. The case fatality rate of these events approximates 50{\%} due to rapid exsanguination. A novel, compliant balloon specifically designed for use in the SVC may provide hemostasis in the event of endovascular perforation. By temporarily occluding the compromised vessel, the endovascular balloon should delay hemodynamic collapse, provide a more controlled surgical field for repair, and thereby reduce the mortality of SVC tears complicating transvenous lead extraction. Objective: To assess the early impact of the compliant endovascular balloon on the management of SVC tears and survival outcomes. Methods: We searched a publicly available, United States Food and Drug Administration-maintained database for adverse events from 1 manufacturer of lead extraction tools. Reports from July 1, 2016, to December 31, 2016 were reviewed by 2 physicians to identify instances of SVC tears. Extracting physicians were contacted for further case details. Confirmed SVC tears were analyzed for patient demographics, repair strategies, and index hospitalization mortality. Results: Of the complications reported, 35 cases of surgically confirmed SVC tears were identified. One hundred percent of patients (9/9) were discharged alive when the endovascular balloon was properly utilized, compared to 50{\%} of patients (13/26) when the device was not used (P = .0131). Differences between all other variables analyzed were statistically insignificant. Conclusion: During the study period, we observed a reduction in mortality in patients who suffered SVC tears while undergoing lead extraction when treatment included an endovascular balloon.",
keywords = "Balloon, Cardiac device, Endovascular, Laceration, Lead extraction, Repair, Superior vena cava, Tear",
author = "Ryan Azarrafiy and Tsang, {Darren C.} and Boyle, {Thomas A.} and Wilkoff, {Bruce L.} and Roger Carrillo",
year = "2017",
doi = "10.1016/j.hrthm.2017.05.005",
language = "English (US)",
journal = "Heart Rhythm",
issn = "1547-5271",
publisher = "Elsevier",

}

TY - JOUR

T1 - Compliant endovascular balloon reduces the lethality of superior vena cava tears during transvenous lead extractions

AU - Azarrafiy, Ryan

AU - Tsang, Darren C.

AU - Boyle, Thomas A.

AU - Wilkoff, Bruce L.

AU - Carrillo, Roger

PY - 2017

Y1 - 2017

N2 - Background: Superior vena cava (SVC) lacerations have been identified as the most lethal complication encountered during cardiac implantable electronic device lead extraction. The case fatality rate of these events approximates 50% due to rapid exsanguination. A novel, compliant balloon specifically designed for use in the SVC may provide hemostasis in the event of endovascular perforation. By temporarily occluding the compromised vessel, the endovascular balloon should delay hemodynamic collapse, provide a more controlled surgical field for repair, and thereby reduce the mortality of SVC tears complicating transvenous lead extraction. Objective: To assess the early impact of the compliant endovascular balloon on the management of SVC tears and survival outcomes. Methods: We searched a publicly available, United States Food and Drug Administration-maintained database for adverse events from 1 manufacturer of lead extraction tools. Reports from July 1, 2016, to December 31, 2016 were reviewed by 2 physicians to identify instances of SVC tears. Extracting physicians were contacted for further case details. Confirmed SVC tears were analyzed for patient demographics, repair strategies, and index hospitalization mortality. Results: Of the complications reported, 35 cases of surgically confirmed SVC tears were identified. One hundred percent of patients (9/9) were discharged alive when the endovascular balloon was properly utilized, compared to 50% of patients (13/26) when the device was not used (P = .0131). Differences between all other variables analyzed were statistically insignificant. Conclusion: During the study period, we observed a reduction in mortality in patients who suffered SVC tears while undergoing lead extraction when treatment included an endovascular balloon.

AB - Background: Superior vena cava (SVC) lacerations have been identified as the most lethal complication encountered during cardiac implantable electronic device lead extraction. The case fatality rate of these events approximates 50% due to rapid exsanguination. A novel, compliant balloon specifically designed for use in the SVC may provide hemostasis in the event of endovascular perforation. By temporarily occluding the compromised vessel, the endovascular balloon should delay hemodynamic collapse, provide a more controlled surgical field for repair, and thereby reduce the mortality of SVC tears complicating transvenous lead extraction. Objective: To assess the early impact of the compliant endovascular balloon on the management of SVC tears and survival outcomes. Methods: We searched a publicly available, United States Food and Drug Administration-maintained database for adverse events from 1 manufacturer of lead extraction tools. Reports from July 1, 2016, to December 31, 2016 were reviewed by 2 physicians to identify instances of SVC tears. Extracting physicians were contacted for further case details. Confirmed SVC tears were analyzed for patient demographics, repair strategies, and index hospitalization mortality. Results: Of the complications reported, 35 cases of surgically confirmed SVC tears were identified. One hundred percent of patients (9/9) were discharged alive when the endovascular balloon was properly utilized, compared to 50% of patients (13/26) when the device was not used (P = .0131). Differences between all other variables analyzed were statistically insignificant. Conclusion: During the study period, we observed a reduction in mortality in patients who suffered SVC tears while undergoing lead extraction when treatment included an endovascular balloon.

KW - Balloon

KW - Cardiac device

KW - Endovascular

KW - Laceration

KW - Lead extraction

KW - Repair

KW - Superior vena cava

KW - Tear

UR - http://www.scopus.com/inward/record.url?scp=85020288325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020288325&partnerID=8YFLogxK

U2 - 10.1016/j.hrthm.2017.05.005

DO - 10.1016/j.hrthm.2017.05.005

M3 - Article

C2 - 28506914

AN - SCOPUS:85020288325

JO - Heart Rhythm

JF - Heart Rhythm

SN - 1547-5271

ER -